Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
Go back to Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.43 +0.09 (1.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.34 | 52 Week High | $18.00 | |||
| Open | $5.29 | 52 Week Low | $6.91 | |||
| Day High | $5.45 | P/E | N/A | |||
| Day Low | $5.29 | EPS | $-0.67 | |||
| Volume | 589,450 | |||||
